Original article

Blood Transfusion - 6 2020 (November-December)

The effect of pathogen inactivation on cryoprecipitate: a functional and quantitative evaluation

Authors

Key words: data-independent acquisition, DIA, microflow liquid chromatography, cryoprecipitate, pathogen inactivation
Publication Date: 2020-08-06

Abstract

Background -  Background - As a pooled donor blood product, cryoprecipitate (cryo) carries risks of pathogen transmission. Pathogen inactivation (PI) improves the safety of cryoprecipitate, but its effects on haemostatic properties remain unclear. This study investigated protein expression in samples of pathogen inactivated cryoprecipitate (PI-cryo) using non-targeted quantitative proteomics and in vitro haemostatic capacity of PI-cryo.
Materials and methods - Whole blood (WB)- and apheresis (APH)-derived plasma was subject to PI with INTERCEPT® Blood System (Cerus Corporation, Concord, CA, USA) and cryo was prepared from treated plasma. Protein levels in PI-cryo and paired controls were quantified using liquid chromatography-tandem mass spectrometry. Functional haemostatic properties of
PI-cryo were assessed using a microparticle (MP) prothrombinase assay, thrombin generation assay, and an in vitro coagulopathy model subjected to thromboelastometry.
Results - Over 300 proteins were quantified across paired PI-cryo and controls. PI did not alter the expression of coagulation factors, but levels of platelet-derived proteins and platelet-derived MPs were markedly lower in the WB PI-cryo group. Compared to controls, WB (but not APH) cryo samples demonstrated significantly lower MP prothrombinase activity, prolonged clotting time, and lower clot firmness on thromboelastometry after PI. However, PI did not affect overall thrombin generation variables in either group.
Discussion - Data from this study suggest that PI via INTERCEPT® Blood System does not significantly impact the coagulation factor content or function of cryo but reduces the higher MP content in WB-derived cryo. PI-cryo products may confer benefits in reducing pathogen transmission without affecting haemostatic function, but further in vivo assessment is warranted.

Downloads

Authors

Reed W. Kamyszek1 - Department of Anesthesiology, University of Michigan, Ann Arbor, MI; Duke University School of Medicine, Durham, NC

Matthew W. Foster - Duke Proteomics and Metabolomics Shared Resource, Durham, NC

Brooke A. Evans - Duke University School of Medicine, Durham, NC

Keaton Stoner - Duke University Department of Biology, Durham, NC

Jessica Poisson - Department of Pathology, Duke University Medical Center, Durham, NC

Amudan J. Srinivasan - Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

J. Will Thompson - Duke Proteomics and Metabolomics Shared Resource, Durham, NC

M. Arthur Moseley - Duke Proteomics and Metabolomics Shared Resource, Durham, NC

Micah J. Mooberry - Department of Medicine, University of North Carolina Medical Center, Chapel Hill, NC

Ian J. Welsby - Department of Anesthesiology, Duke University Medical Center, Durham, NC, United States of America

  • Abstract viewed - 208 times
  • PDF downloaded - 98 times